Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imlygic

- PMLiVE

Has Amgen cracked KRAS? First clinical data says maybe

Progess on cancer 'master switch'

- PMLiVE

Encouraging early data for Amgen’s BiTE therapies

Including first-in-man data from prostate cancer drug

- PMLiVE

Amgen buys Danish partner Nuevolution for $167m

Copenhagen-based biotech will remain autonomous

- PMLiVE

Boehringer eyes rare disease use for respiratory blockbuster

Would help support respiratory franchise

- PMLiVE

So far so good for Amgen’s much-anticipated KRAS inhibitor

Promise to hit previously 'undruggable' target

- PMLiVE

AZ invests more in IO with Transgene oncolytic virus deal

Opportunity for combinations with IO pipeline

- PMLiVE

With Spiriva under pressure, Boehringer moves to bolster pipeline

Forges alliance with PureTech Health

- PMLiVE

Amgen and UCB’s Evenity finally approved, but with label warnings

Drug unlikely to match Prolia's revenues

- PMLiVE

Novartis and Amgen come to blows over migraine partnership

Amgen seeks to terminate contract

- PMLiVE

Amgen, Servier heart failure drug clears trial hurdle

Drug could be a blockbuster - if it hits key endpoints

- PMLiVE

CHMP recommends new Keytruda dosing schedule

Will apply to eight indications across five tumour types

- PMLiVE

Boehringer’s IL-36-targeting drug tackles rare form of psoriasis

Antibody would be first-in-class

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links